Clinical Trials Sponsored by Lutris Pharma Ltd.

Total 1230 results

Lutris Pharma Ltd.

Recruiting

LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

EGFRI Induced Acneiform Lesions

United States, Israel
Lutris Pharma Ltd.

Completed

A Study of LUT014 in Patients With Metastatic Colorectal Cancer With EGFR Inhibitor Induced Acneiform Lesions

EGFR Inhibitor Induced Acneiform Lesions

United States, Israel
Lutris Pharma Ltd.

Completed

LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients

Radiation Dermatitis

United States
AJU Pharm Co., Ltd.
OM Pharma SA

Recruiting

The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Chronic Prostatitis With Chronic Pelvic Pain Syndrome | Chronic Prostatitis | Chronic Pelvic Pain Syndrome

Korea, Republic of
N4 Pharma UK Ltd.
BDD Pharma Ltd

Completed

Pharmacoscintigraphic Study to Evaluate Two Sildenafil Products

Erectile Dysfunction

United Kingdom
Tris Pharma, Inc.

Completed

Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic

Diabetic Polyneuropathy

Germany, United Kingdom
Tris Pharma, Inc.

Terminated

CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer (CORAL)

Neoplasms | Pain | Chronic Pain

Croatia, Austria, Belgium, Bulgaria, Denmark, Germany, Hungary, Poland, Romania, Serbia, Slovakia, Chile, Spain, United Kingdom
Tris Pharma, Inc.

Completed

TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity

United States
Tris Pharma, Inc.

Completed

Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study

Attention Deficit Hyperactivity Disorder

United States
University Hospital, Grenoble
NETRIS Pharma

Recruiting

Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma (LAP-NET1)

Pancreatic Ductal Adenocarcinoma

France
Centre Leon Berard
NETRIS Pharma

Completed

First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors (NP137)

Advanced Solid Tumor | Endometrial Carcinoma | Hormone Receptor Positive

France
Tris Pharma, Inc.

Recruiting

Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain.

Pain

Netherlands
Tris Pharma, Inc.

Completed

Assessment of Abuse Potential of Cebranopadol in Humans

Human Abuse Potential

United States
Tris Pharma, Inc.

Completed

A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users

Abuse, Drug

Canada
Tris Pharma, Inc.

Completed

Bunionectomy Trial With GRT6005

Post Operative Pain

United States
Tris Pharma, Inc.

Completed

Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves

Diabetes Mellitus | Diabetic Neuropathies | Chronic Pain

France, Spain, Austria, United States, Denmark, Germany, Italy, Netherlands
Tris Pharma, Inc.

Completed

CORAL XT - Open-label Extension Trial of the CORAL Trial (CORAL XT)

Neoplasms | Pain | Chronic Pain

Austria, Belgium, Bulgaria, Denmark, Germany, Hungary, Poland, Romania, Serbia, Slovakia
Tris Pharma, Inc.

Completed

Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years

Attention Deficit Hyperactivity Disorder

United States
Centre Leon Berard
NETRIS Pharma

Recruiting

Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] (AML-NET)

Acute Myeloid Leukemia Refractory

France
Centre Leon Berard
NETRIS Pharma

Recruiting

NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies (IMMUNONET)

Advanced Solid Tumors | Metastatic Solid Tumors

France
University Hospital, Grenoble
NETRIS Pharma

Recruiting

Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC (Liver-NET1)

Hepatocellular Carcinoma

France
UroGen Pharma Ltd.

Not yet recruiting

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (UTOPIA)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma
Artios Pharma Ltd

Recruiting

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Advanced Solid Tumor | Metastatic Solid Tumor

United States
Elgan Pharma Ltd.

Not yet recruiting

Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

Intestinal Malabsorption
UroGen Pharma Ltd.

Recruiting

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer | Non-muscle Invasive Bladder Cancer | Urothelial Carcinoma Bladder | NMIBC | Urothelial Carcinoma Recurrent | Carcinoma in Situ of Bladder

United States, Italy, Spain
Reneo Pharma Ltd

Completed

An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients (STRIDE)

Primary Mitochondrial Myopathy

United States, Spain, Australia, France, United Kingdom, New Zealand, Denmark, Norway, Czechia, Belgium, Canada, Germany, Hungary, Italy, Netherlands
Small Pharma Ltd

Completed

IM and IV SPL026 Drug Product in Healthy Participants

Major Depressive Disorder

United Kingdom
Artios Pharma Ltd

Active, not recruiting

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Breast Cancer | Metastatic Cancer | Advanced Cancer

United States, United Kingdom
Immunity Pharma Ltd.

Suspended

A Study of IPL344 in the Treatment of ALS Patients (ALS)

Amyotrophic Lateral Sclerosis

Israel
Mapi Pharma Ltd.

Completed

A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

Multiple Sclerosis, Relapsing-Remitting

United States, Belarus, Bosnia and Herzegovina, Bulgaria, Estonia, Georgia, Israel, Moldova, Republic of, Russian Federation, Ukraine
Mapi Pharma Ltd.

Active, not recruiting

Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS

Primary Progressive Multiple Sclerosis

Israel, Moldova, Republic of
Artios Pharma Ltd

Completed

Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein (ATM)

Solid Tumor, Unspecified, Adult

United States, United Kingdom
Reneo Pharma Ltd

Completed

A Study of the Safety of REN001 in Patients With McArdle Disease

McArdle Disease

Spain, United Kingdom
Acacia Pharma Ltd

Completed

PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment

Renal Disease, End Stage

United States
Ziarco Pharma Ltd

Completed

A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis

Psoriasis

Belgium, Germany, Poland, United Kingdom
Ziarco Pharma Ltd

Completed

A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Atopic Dermatitis

Atopic Dermatitis

Belgium, Germany, Poland, United Kingdom
UroGen Pharma Ltd.

Completed

The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study (Olympus)

Carcinoma, Transitional Cell | Transitional Cell Carcinoma of Renal Pelvis

United States, Israel
Acacia Pharma Ltd

Completed

Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy

CINV

Denmark
Reneo Pharma Ltd

Terminated

A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy

Primary Mitochondrial Myopathy

United Kingdom
Acacia Pharma Ltd

Completed

European Phase III Study of APD421 in PONV

PONV

France, Germany
Intec Pharma Ltd.

Unknown

A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients (Accordance)

Parkinson's Disease

United States, Spain, Italy, Israel, Poland, United Kingdom, Bulgaria, Germany, Slovakia, Ukraine
Topivert Pharma Ltd

Completed

Study of TOP1630 for Dry Eye Syndrome (THEIA-1)

Dry Eye Syndrome

United States
Acacia Pharma Ltd

Completed

Phase II Dose-ranging Study of APD421 in PONV

Postoperative Nausea and Vomiting

United States, Germany, France
Topivert Pharma Ltd

Completed

Study for Safety and Tolerability of TOP1288 Administered Orally in Healthy Subjects

Ulcerative Colitis

United Kingdom
Intec Pharma Ltd.

Unknown

A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004

Parkinson's Disease

United States, Israel, Italy, Spain, United Kingdom, Bulgaria, Germany, Poland, Slovakia, Ukraine
Izun Pharma Ltd

Completed

Safety and Efficacy of IZN-6N4 Oral Rinse for the Prevention of Oral Mucositis in Patients With Head and Neck Cancer

Oral Mucositis

United States, Israel
Bioblast Pharma Ltd.

Completed

Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients (HOPEMD)

Oculopharyngeal Muscular Dystrophy

United States, Israel, Canada
Topivert Pharma Ltd

Completed

Study for Safety and Tolerability of TOP1288 Administered Rectally in Healthy and Ulcerative Colitis Subjects

Ulcerative Colitis

United Kingdom
Spirig Pharma Ltd.

Terminated

Observational Trial Tolerability and Efficacy of Resiquimod Gel in Patients Treated for Actinic Keratosis.

Actinic Keratosis

Switzerland, Germany
Spirig Pharma Ltd.

Terminated

Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma

Nodular Basal Cell Carcinoma

Germany, Switzerland

Clinical Trials Sponsored by Lutris Pharma Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations